Last reviewed 2026-04-20 · How we verify

Amphotericin B Liposome

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Chills
• Nausea
• Vomiting
• Diarrhea
• Hyperglycemia
• Creatinine increased
• Alkaline phosphatase increased
• BUN increased
• Hypomagnesemia
• Headache
• Abdominal pain
• Bilirubinemia

Serious adverse events

• Sepsis
• Gastrointestinal hemorrhage
• Hypoxia
• Infection

Key clinical trials

• Human Bioequivalence Study of Liposomal Amphotericin B for Injection (NA)
• Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) (PHASE3)
• Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment (PHASE2)
• Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT) (PHASE3)
• Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections (PHASE2)
• A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis
• Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic Dysfunction (NA)
• Platform Trial For Cryptococcal Meningitis (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Amphotericin B Liposome CI brief — competitive landscape report
• Amphotericin B Liposome updates RSS · CI watch RSS
• Aurobindo Pharma Ltd portfolio CI